Robert Griffin
Wyomissing, PANPI 1528064318
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,202 of the $5,562 with a category attached, or 75.6%. It is spread thinly across 23 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,218 and has fallen 98.7% since, to $42 in 2023.
Across 269 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Planmeca USA, Inc.$1K
- Novartis$520
- Amgen$460
- Pfizer$402
- Johnson & Johnson$362
- Genentech USA, Inc.$351
- plus $2K from 17 others
Across 167 payments — averaging $4050.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$283K
- Gilead$201K
- Astrazeneca UK Limited$66K
- Pfizer$31K
- Merck$28K
- E.r. Squibb & Sons, L.L.C.$26K
- plus $41K from 7 others
What the payments were for
- Speaking & faculty fees$1,32624%
- Food & beverage$4,20276%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Planmeca USA, Inc. | 1 | $1,326 |
| Novartis | 30 | $520 |
| Amgen(2 entities) | 30 | $460 |
| Pfizer | 36 | $402 |
| Johnson & Johnson(2 entities) | 17 | $362 |
| Genentech USA, Inc. | 23 | $351 |
| AbbVie | 17 | $291 |
| Sanofi | 11 | $225 |
| E.r. Squibb & Sons, L.L.C. | 14 | $224 |
| UCB, Inc. | 14 | $210 |
| Lilly USA, LLC | 9 | $180 |
| Radius Health, Inc. | 7 | $161 |
| GSK | 13 | $155 |
| Medexus Pharma, Inc. | 14 | $147 |
| AstraZeneca(2 entities) | 10 | $139 |
| Sobi, Inc | 6 | $109 |
| Actelion Pharmaceuticals US, Inc. | 5 | $92 |
| Ferring Pharmaceuticals Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $43 |
| Bristol Myers Squibb | 3 | $40 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Planmeca Dental X-Ray$1,326
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.